IMMUTEP LIMITED — Director's Dealing 2015

Jan 6, 2015

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: PRIMA BIOMED LIMITED (ASX:PRR) ACN:[90 009 237 889 ]

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Mr Marc Voigt Date of Last Notice: 15 July 2014

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	02 January 2015

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change		1) Ordinary Fully Paid Shares	1) Ordinary Fully Paid Shares	1) Ordinary Fully Paid Shares	1) Ordinary Fully Paid Shares
			Shares	Options
		Direct	720,000	1,171,754
		Indirect	-	-
		**Total **	720,000	**1,171,754 **
Class		Ordinary Fully Paid Shares
Number acquired		1) Ordinary Fully Paid Shares			Options - - -
			Shares		Options
		Direct	150,000		-
		Indirect	-		-
		Total	150,000		-
Number disposed		Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		A$ 5,100

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change		1) Ordinary Fully Paid Shares Shares Options Direct 870,000 1,171,754 Indirect - - Total 870,000 1,171,754 2) American Depositary Receipts (ADR) Shares Options Direct 150 - Indirect - - Total 150 - 3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Acquiring 150,000 fully paid ordinary shares on market at $0.034 each.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 - +Closed Period

Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded duringa +closedperiod whereprior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed duringthisperiod?
If prior written clearance was provided on what date was this provided?
	02.01.2015

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002